Maryland Board of Pharmacy Public Board Meeting

Agenda May 18, 2022

Name	Title	Present	Absent
Bouyoukas, S.	Commissioner		
Evans, K.	Commissioner		
Fink, K.	Commissioner		
Hardesty, J.	Commissioner/President		
Geigher, P.	Commissioner		
Leikach, N.	Commissioner/Treasurer		
Morgan, K.	Commissioner		
Oliver, B	Commissioner		
Rusinko, K.	Commissioner/Secretary		
Vacant	Commissioner		
Vasquez, J.	Commissioner		
Yankellow, E.	Commissioner		
Bethman, L.	Board Counsel		
Felter, B.	Board Counsel		
Speights-Napata, D.	Executive Director		
Green, J.	Acting IT Director		
James, D.	Licensing Manager		
Leak, T.	Compliance Director		
Reed, J.	Legislative Liaison		

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
Chew, C.		Enforcement Compliance Auditor	
I. Executive Committee Report(s)	A.) J. Hardesty, Board President B.)K. Rusinko, Secretary	 Members of the Board with a conflict of interest relating to any item on the agenda are advised to notify the Board at this time or when the issue is addressed in the agenda. 1. Call to Order 2. Sign-in Introduction and of meeting attendees – (Please indicate on sign-in sheet if you are requesting CE Units for attendance) 3. Distribution of Agenda and packet materials 4. Review and approve April 2022 Public Meeting Minutes 	
II. A. Executive Director Report B. New Business	D. Speights- Napata, Executive Director J. Hardesty,	1. Meetings Update 2. Staffing Update	
C. Operations	Board President J. Green, Acting IT Director	1. Procurement and Budget Updates	
D. Licensing	E. Bouyoukas, Commissioner	1. Unit Updates 2. Monthly Statistics	

Subject	Responsible Party		1	Discussion			Action Due Date (Assigned To)
		License Type	New	Renewed	Reinstated	Total	
		Distributor	12	0	0	1,490	
		Pharmacy	8	612	0	2,103	
		Pharmacist	29	452	0	12,623	
		Vaccination	21	140	0	5,637	
		Pharmacy Intern - Graduate	0	0	0	39	
		Pharmacy Intern - Student	19	7	0	504	
		Pharmacy Technician	151	272	6	9,921	
		Pharmacy Technician- Student	2	0	0	42	
		TOTAL	242	1,483	6	32,359	
E. Compliance	Compliance Director		ed Sterile In spection Fo	nspection For orm V 1.2	m for Board	Approval	
		Complaints & Inve	estigations:				

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
		New Complaints – 52	
		 Medication Error - 3 Dispensing Error - 1 Employee Pilferage - 1 Unprofessional Conduct - 1 Unlicensed Personnel - 1 Compounding Issues - 3 Refusal to Fill - 2 Customer Service - 5 Inspection Issues - 22 Out of State Disciplinary Actions - 13 Resolved (Including Carryover) - 34 Actions within Goal - 14/34 Final disciplinary actions taken - 6 Summary Actions Taken - 0 	
		Average days to complete – N/A Inspections: Total - 191 Annual Regulatory Inspections – 139 COVID Vaccine Storage Inspections – 42 Narcotic Audit Follow Ups – 1 Opening Inspections – 3 Closing Inspections – 2 Relocation/Change of Ownership Inspections – 2 Board Special Investigation Inspections – 0 Attempted Inspections – 2 Pending Openings # 2 Pending Closing # 1	

	Responsible		Action Due Date
Subject	Party	Discussion	(Assigned To)

F. Legislation & Regulations	J. Reed, Legislative Liaison	 COMAR 10.34.41 (Administration of a Maintenance Injectable Medication) request to ratify responses to public comments request to ratify responses to public comments 2 request to adopt regulation without amendments COMAR 10.34.34 (Validated Pharmacy Technician) request to submit regulation to MDH with substantial amendments 	
III. Committee Reports	Evans, K. Commissioner	Drug Therapy Management	
A. Practice Committee		 1. University of Maryland, School of Pharmacy, Center for Innovative Pharmacy Solutions Pharmacist: Charmaine Rochester-Eyeguokan. Protocols: Metabolic syndrome, and tobacco use and dependence protocols. 	
		 2. Chase Brexton Pharmacists: Kierra Dotson and Mackenzie Hrubey. Protocols: HIV primary care management and pharmacy adherence support team. 	
		 3. Chase Brexton Pharmacists: Hassan Bashir and Andrea Chapdelaine. Protocol: Anticoagulation. 	
		4. MedStar	

 Pharmacists: Nicole Brandt, Bindu Mathews, and Erica Wilson. Protocols: Chronic obstructive pulmonary disease, ASCVD risk reduction, hypertension, neurocognitive disorder, and diabetes mellitus management. Commissioner K. Evans Recused 	
 Wilson. Protocols: Chronic obstructive pulmonary disease, ASCVD risk reduction, hypertension, neurocognitive disorder, and diabetes mellitus management. Commissioner K. Evans Recused 	
 Protocols: Chronic obstructive pulmonary disease, ASCVD risk reduction, hypertension, neurocognitive disorder, and diabetes mellitus management. Commissioner K. Evans Recused 	
ASCVD risk reduction, hypertension, neurocognitive disorder, and diabetes mellitus management. Commissioner K. Evans Recused	
disorder, and diabetes mellitus management. Commissioner K. Evans Recused	
Commissioner K. Evans Recused	
Questions	
Question One: Kaiser Permanente Mid-Atlantic States	
Two pharmacy locations desire to utilize mobile Germfree	
Rental Compounding Pharmacy trailers while their cleanrooms	
are renovated. The trailers will be rendered immoveable and	
comply with USP 797 and USP 800. Additionally, the trailers	
will be inspected by an outside vendor to ensure compliance	
with USP 707 and USP 800. If approved, the trailer will be	
inspected by the Board prior to it being utilized. The trailers will meet all other requirements for a pharmacy, including	
those for sterile compounding. COMAR 10.34.19.09.	
those for sterne compounding. ColviAR 10.54.17.07.	
Kaiser would like clarify that a mobile structure would be	
permitted.	
Commissioners Bouyoukas and Fink Recused	
Proposed Response One: If a pharmacy for which a permit is	
issued is rendered inoperable, a pharmacist may dispense or	
distribute from a temporary site if the permit holder (1) obtains	
approval from the Board prior to continuing pharmacy	
operations from the temporary site and (2) ensures the	
temporary site complies with all State and federal laws.	
COMAR 10.34.31.08. The Board may approve the operation of a pharmacy from a temporary site for a period not to exceed	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
	1		
		60 days from the date of the original approval, unless an extension is approved by the Board prior to the expiration of the preceding approval. COMAR 10.34.31.08.	
		Question Two: Costco We are planning to begin offering travel medicine services in partnership with a travel medicine group (SafeGard: https://www.sgtravelmed.com/)	
		In short, the process is as follows:	
		 patient fills out a pre-travel form online nurses and physicians at SafeGard review the form, and provide recommendations for travel-related vaccines and medications pharmacist reviews Safegard's recommendations, discusses them with the patient, and provides vaccines and medications. 	
		Can Costco include travel medicines in a collaborative drug therapy management protocol? For example, if SafeGard recommends Azithromycin for traveler's diarrhea or a medication for malaria prophylaxis, can Costco include that in a protocol or would the pharmacy need to obtain a prescription?	
		Proposed Response Two: A pharmacist must obtain a valid prescription prior to dispensing travel related medications. Alternatively, the authorized prescribers and dispensing pharmacist could enter a prescriber-pharmacist agreement and the pharmacist could provide drug therapy management services pursuant to guidelines documented in a drug therapy	

Subject	Responsible Party	Discussion	Action Due Date (Assigned To)
B. Licensing Committee	K. Rusinko, Chair	1. Review of Pharmacist Applications:	
		a. 133096 - Applicant would like to use her work history as regulatory project manager as her 520 intern hours. <i>Committee recommendation: Approve</i>	
		b. E.K -Applicant is requesting to waive the TOEFL examination of the FPGEC requirement for NABP. Committee recommendation: Approve	
		c. 131027 - Applicant is requesting to take the MPJE for the sixth time. Committee recommendation: Approve	
		 d. 129695 - Applicant is requesting to take the MPJE for the sixth time. Committee recommendation: Approve 	
		2. Review of Pharmacy Intern Applications:	
		a. B.C- Requesting to extend intern license that expires on 5/31/2022	
		Committee recommendation: Deny. Unable to extend further than the maximum. Can register as a technician if they meet the requirements.	

3. Review of Pharmacy Technician Applications: NONE

6. Review of Pharmacy Technicians Training Programs:

Review of Distributor Applications: NONE

5. Review of Pharmacy Applications: NONE

NONE

7. New Business: NONE

Subject Responsible Party	Discussion	Action Due Date (Assigned To)
---------------------------	------------	----------------------------------

C. Public Relations Committee	E. Yankellow, Chair	Public Relations Committee Update:
D. Disciplinary	N. Leikach, Chair	Disciplinary Committee Update
E. Emergency Preparedness Task Force	N. Leikach, Chair	Emergency Preparedness Task Force Update
IV. Other Business & FYI	J. Hardesty, President	
V. Adjournment	J. Hardesty, President	 A. The Public Meeting was adjourned. B. I would like to ask for a motion to close the public meeting and open a closed public session for the purpose of engaging in medical review committee deliberations of confidential matters contained in licensure applications in accordance with General Provisions Article Section 3-305(b)(13). C. J. Hardesty convened a Closed Public Session to conduct a medical review committee evaluation of confidential applications. D. The Closed Public Session was adjourned. Immediately thereafter, J. Hardesty, convened an Administrative Session for purposes of discussing confidential disciplinary cases. E. With the exception of cases requiring recusals, the Board members present at the Public Meeting continued to participate in the Closed Public Session and the Administrative Session.